Log in to search using one of your social media accounts:

 

Health Tip: Understanding COPD

Title: Health Tip: Understanding COPDCategory: Health NewsCreated: 11/10/2017 12:00:00 AMLast Editorial Review: 11/10/2017 12:00:00 AM
Source: MedicineNet Lungs General - Category: Respiratory Medicine Source Type: news

Related Links:

Authors: Yang X, Huo B, Zhong X, Su W, Liu W, Li Y, He Z, Bai J Abstract Human regulatory T cells (Tregs) have been reported to be not significantly different in the peripheral blood of patients with chronic obstructive pulmonary disease (COPD) and healthy controls. Recent research has identified some new markers for Tregs and indicated that Tregs are composed of distinct subpopulations. The aim of the study was to describe the changing patterns of circulating Treg subpopulations in patients with acute exacerbation of COPD (AECOPD) and healthy controls, and to explore their potential roles in AECOPD pathogenesis. B...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - Category: Respiratory Medicine Tags: COPD Source Type: research
Authors: Marçôa R, Rodrigues DM, Dias M, Ladeira I, Vaz AP, Lima R, Guimarães M Abstract Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality worldwide. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) project has been working to improve awareness, prevention and management of this disease. The aim of this study is to evaluate how COPD patients are reclassified by the 2017 GOLD system (versus GOLD 2011), to calculate the level of agreement between these two classifications in allocation to categories and to compare the performance of each clas...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - Category: Respiratory Medicine Tags: COPD Source Type: research
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, 'FF/UMEC/VI') for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news
Authors: Köhler D, Dellweg D Abstract Numerous studies have shown that exacerbation rates in COPD can be significantly reduced by long acting beta-2-agonists (LABA), long acting anticholinergic agents (LAMA) and inhaled steroids (ICS). Elaborate and extensive investigations however failed to prove that the reduction in exacerbation rates leads to life prolongation. As opposed to this, numerous studies have shown a reduction in life expectancy with increasing number and severity of exacerbations.This review aimed at comparing these studies and to elaborate the relevance and reduction of exacerbations rates by L...
Source: Pneumologie - Category: Respiratory Medicine Tags: Pneumologie Source Type: research
We studied the prevalence, burden and potential risk factors for chronic bronchitis symptoms in the Burden of Obstructive Lung Disease study. Representative population-based samples of adults aged ≥40 years were selected in participating sites. Participants completed questionnaires and spirometry. Chronic bronchitis symptoms were defined as chronic cough and phlegm on most days for ≥3 months each year for ≥2 years. Data from 24 855 subjects from 33 sites in 29 countries were analysed. There were significant differences in the prevalence of self-reported symptoms meeting our definition of chronic bro...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: COPD and smoking Original Articles: COPD Source Type: research
The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial. To evaluate the prevalence and stability of a high level of blood eosinophils (≥300 cells·μL–1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis. In COPD patients, 15.8...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: COPD Source Type: research
In March 2017, the European Union (EU) celebrated its 60th anniversary. The frenzied focus in recent times has been on crises, from economics to migration, terrorism and the UK leaving the EU. However, in contrast to the increase in Euroscepticism are the EU's successes, which should and must be celebrated. One of the major victories from a public health perspective is the harmonisation of tobacco control policy across the 28 EU member states (MSs) through the Tobacco Products Directive (TPD) and the Tobacco Tax Directive, which, through the regulation of tobacco products, protect the health of the 511 million EU citizens.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: COPD and smoking Original Articles: European lung corner Source Type: research
The identification of factors that may predict success in smoking cessation efforts is highly desirable as this could help to match smokers with a strategy more likely to help them quit, as well as helping to optimise healthcare resources and refine state-funded tobacco policies. Although several factors have been extensively investigated, both in aided and unaided smoking cessation, no consistent determinants of smoking cessation have been identified [1].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: COPD and smoking Original Articles: Correspondence Source Type: research
Chronic obstructive pulmonary disease (COPD) is associated with acute and chronic pulmonary as well as systemic inflammation [1]. Anti-inflammatory treatments, such as inhaled corticosteroids (ICS) and oral roflumilast, are recommended for COPD patients [2]. These drugs are effective agents for the prevention of COPD exacerbations and improvement of lung function and have various effects on health status, but they are associated with adverse events, the most concerning being pneumonia (ICS) and diarrhoea (roflumilast).
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: COPD and smoking Editorials Source Type: research
Overweight in patients with chronic obstructive pulmonary disease needs more attention: a cross-sectional study in general practice, Published online: 22 November 2017; doi:10.1038/s41533-017-0065-3Doctors should pay more attention to weight management in patients with mild chronic lung disease, say researchers in the Netherlands. While guidelines for treating chronic obstructive pulmonary disease (COPD) focus primarily on preventing weight-loss in severe COPD, around 65 per cent of patients with mild COPD are overweight or obese. Excessive weight exacerbates symptoms and triggers co-morbidities, and so can impact heavily ...
Source: npj Primary Care Respiratory Medicine - Category: Primary Care Authors: Source Type: research
More News: Chronic Obstructive Pulmonary | Respiratory Medicine